## TROW: T. Rowe Price Group, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 -0.3% below STRENGTH zone (3.0-6.0%); PEG 3.53 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Keysight Technologies Inc. $KEYS Shares Acquired by Russell Investments Group Ltd.**
- Source: MarketBeat | 20251201T113610 | Somewhat-Bullish | Relevance: 75%
- Russell Investments Group Ltd. significantly increased its stake in Keysight Technologies Inc. (NYSE:KEYS) by 30.1% in Q2, acquiring 180,465 shares valued at approximately $29.58 million. Keysight also reported strong Q4 earnings, exceeding revenue and EPS expectations, and announced a new $1.5 billion share buyback program, signaling management's belief that the stock is undervalued. Analysts have issued a "Moderate Buy" rating for KEYS with an average target price of $214.82.

**2. Grantham Mayo Van Otterloo & Co. LLC Lowers Position in Freeport-McMoRan Inc. $FCX**
- Source: MarketBeat | 20251130T103506 | Neutral | Relevance: 75%
- Grantham Mayo Van Otterloo & Co. LLC significantly reduced its stake in Freeport-McMoRan Inc. ($FCX) by 50.0% in Q2, selling 599,386 shares. Despite this, other major institutions like Nuveen LLC, Amundi, Crake Asset Management LLP, Price T Rowe Associates Inc. MD, and Mizuho Markets Cayman LP either bought new positions or materially increased their holdings, contributing to approximately 80.77% institutional ownership. Freeport-McMoRan recently surpassed quarterly EPS and revenue estimates, maintains a quarterly dividend, and holds an average "Buy" analyst rating with a target price of $46.73.

**3. WealthTrust Axiom LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251129T134221 | Neutral | Relevance: 74%
- WealthTrust Axiom LLC reduced its stake in Gilead Sciences by 12.3% in Q2 2025, selling 6,258 shares but still holding 44,574 shares worth approximately $4.94 million. Despite this reduction, many other institutional investors increased their positions, including Vanguard, Geode Capital Management, Price T Rowe Associates Inc. MD, UBS AM, and Nuveen LLC. The article also details Gilead's strong Q3 earnings, FY2025 guidance, dividend announcement, and recent insider stock sales.

**4. Global Retirement Partners LLC Makes New Investment in Intercontinental Exchange Inc. $ICE**
- Source: MarketBeat | 20251130T092720 | Neutral | Relevance: 73%
- Global Retirement Partners LLC has made a new investment in Intercontinental Exchange Inc. (NYSE:ICE), purchasing 3,639 shares valued at approximately $668,000. Institutional investors now own 89.30% of ICE, with several major firms significantly increasing their positions. Despite a CEO stock sale, analysts maintain a "Buy" rating with an average target price higher than the current share price.

**5. Goldman Makes a $2 Billion Bet on ‘Boomer Candy’**
- Source: The Wall Street Journal | 20251201T162121 | Somewhat-Bullish | Relevance: 71%
- Goldman Sachs is acquiring Innovator Capital Management for approximately $2 billion, marking a significant investment in the rapidly growing exchange-traded fund (ETF) market that caters to retirees with "boomer candy" funds. Innovator specializes in defined-outcome funds, or buffer funds, which utilize options to protect investors from market downturns while still allowing access to some gains. This acquisition is part of Goldman's strategy to expand its asset-management division and broaden its offerings to clients.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Evercore ISI Gr | $115 | $118 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Evercore ISI Gr | main | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 20 ($0.30M) |
| Sells | 1 ($0.32M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-0.1%)
- Blackrock Inc.: 9.4% (-1.6%)
- State Street Corpora: 6.5% (-2.7%)
- Charles Schwab Inves: 3.6% (+1.1%)
- Geode Capital Manage: 2.8% (+1.0%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.53 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROA 10%, margin 29%). Balance sheet: strong liquidity (11.4x), low leverage (D/E 0.26). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $22.8B |
| Beta | 1.54 |
| 52W Range | $77.85 - $123.55 |
| Short Interest | 7.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.53 |
| Forward P/E | 9.9 |
| Current P/E | 10.5 |
| YoY Growth | 5.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 stable at -0.3% (minimal 5-day change). Below STRENGTH zone by 3.3pp (needs >3.0% for momentum thesis). RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.33% (CS: 56) | Neutral |
| RSI_14 | 49.6 | Neutral |
| MACD Histogram | 0.29 | Bullish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.021x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.59
- **Stop Loss:** $97.35 (4.2% risk)
- **Target:** $105.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 235
- **Position Value:** $23,873.65
- **Portfolio %:** 23.87%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

### Earnings

**Next:** 2026-02-06 (Est: $2.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.54 | $2.81 | +10.5% |
| 2025Q2 | $2.13 | $2.24 | +4.9% |
| 2025Q1 | $2.13 | $2.23 | +4.7% |
| 2024Q4 | $2.21 | $2.12 | -4.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*